The FDA has mandated updated safety labeling for two respiratory syncytial virus vaccines, Pfizer’s Abrysvo and GlaxoSmithKline’s Arexvy, following the identification of an increased risk of Guillan-Barré syndrome.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
